Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 8/20 | 0.65 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.55 |
| ▸ | PPARA | Q07869 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24398832 | 1.00 | LTA4H (0.65) | LTA4HKCNA3ALDH1A1RECQLPLA2G2A | |
| SCHEMBL8955671 | 0.98 | LTA4H (0.67) | LTA4HKCNA3ALDH1A1RECQLPLA2G2A | |
| SCHEMBL5375018 | 0.92 | LTA4H (0.68) | LTA4HKCNA3ALDH1A1RECQLPLA2G2A | |
| SCHEMBL1007090 | 0.92 | KCNA3 (0.73) | LTA4HKCNA3ALDH1A1RECQLHDAC1 | |
| SCHEMBL1007517 | 0.92 | KCNA3 (0.73) | LTA4HKCNA3ALDH1A1RECQLHDAC1 | |
| SCHEMBL1006520 | 0.92 | KCNA3 (0.73) | LTA4HKCNA3ALDH1A1RECQLHDAC1 | |
| SCHEMBL15520744 | 0.92 | LTA4H (0.55) | LTA4HALDH1A1RECQLHDAC1HDAC2 | |
| SCHEMBL1004974 | 0.92 | KCNA3 (0.73) | LTA4HKCNA3ALDH1A1RECQLHDAC1 | |
| SCHEMBL22091892 | 0.92 | LTA4H (0.55) | LTA4HALDH1A1RECQLHDAC1HDAC2 | |
| SCHEMBL812412 | 0.92 | KCNA3 (0.73) | LTA4HKCNA3ALDH1A1RECQLHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877750-B2 | 2-oxy-benzoxazinone derivatives for the treatment of obesity | NORGINE B.V. (NL) | 2014-11-04 | — | — | US | disclosed |
| EP-1143977-B3 | 2-OXY-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY | NORGINE BV (NL) | 2012-10-24 | — | — | EP | disclosed |
| US-20110065697-A1 | 2-OXY-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY | NORGINE B.V. (NL) | 2011-03-17 | — | — | US | disclosed |
| US-7858617-B2 | 2-hexadecyloxy-6-methyl-4H-3,1-benzoxazin-4-one; inhibition of a lipase, esterase or phosphatase enzyme | NORGINE B.V. (NL) | 2010-12-28 | — | — | US | disclosed |
| US-20080161301-A1 | 2-hexadecyloxy-6-methyl-4H-3,1-benzoxazin-4-one; inhibition of a lipase, esterase or phosphatase enzyme | ALIZYME THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | US | disclosed |
| EP-1143977-B1 | 2-OXY-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY | ALIZYME THERAPEUTICS LTD (GB) | 2005-04-20 | — | — | EP | disclosed |
| US-6624161-B2 | Administering 2-oxy substituted benzoxazin-5-one derivative to a human or animal for the prevention or treatment of obesity or an obesity related disorder | ALIZYME THERAPEUTICS LIMITED (GB) | 2003-09-23 | — | — | US | disclosed |
| CN-1359378-A | 2-oxo-4H-3, 1-benzoxazine 4-ones for the treatment of obesity | ALIZYME THERAPEUTICS LTD (GB) | 2002-07-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161301-A1 | 2-hexadecyloxy-6-methyl-4H-3,1-benzoxazin-4-one; inhibition of a lipase, esterase or phosphatase enzyme | LPL, LIPE, PNLIP | LTA4H 157/4885KCNA3 2132/4885ALDH1A1 142/4885 |
| US-20110065697-A1 | 2-OXY-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY | CYP1B1, CYP4X1, ACOX1 | LTA4H 448/4885KCNA3 2086/4885ALDH1A1 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.